uploads/2017/05/strategic-initiatives-1.png

Behind BD’s Recent Strategic Initiatives and Product Launches

By

Updated

Recent product launches

Becton, Dickinson, and Company (BDX), or BD, has a strong portfolio of products. The company also has a strong growth trajectory driven by new and innovative product launches.

In BD Medical, the company recently launched BD Enterprise Pharmogistics 1.0. Its pharmacy inventory management software provides enhanced medication management and patient safety across its healthcare networks and integrates with its Pyxis ES platform, which is BD’s base medication management platform.

In BD Life Sciences segment, the company received 510(k) clearance for its new flow cytometry system BD FACSVia, a cell analysis solution for blood banks and clinical laboratories.

Article continues below advertisement

In its Diabetes business, the company is working with Medtronic (MDT) to relaunch a new infusion set, after the temporary suspension of its shipments. The company received some complaints during its product launch and is now working on product optimization. BD is also set to launch an insulin patch pump in 2H18.

Notably, Boston Scientific (BSX) and Edwards Lifesciences (EW) are the major competitors of BD in the diabetes market. Investors can invest in the Vanguard S&P 500 ETF (VOO) for exposure to BD. VOO has ~0.20% of its total holdings in BD.

Other strategic initiatives

BD acquired Caesarea Medical Electronics on April 4, 2017, in yet another move to strengthen its medication management solutions business. Caesarea Medical Electronics is an Israel-based company that manufactures infusion pump systems.

CareFusion, which BD acquired in 2015, had acquired 40% stake in Caesarea Medical in 2014.

According to Mike Garrison, vice president and general manager of BD’s Worldwide Infusion Solutions, “The integration of CME’s technology into BD will strengthen our strategy of reinventing medication management across the health care continuum. The acquisition of CME advances our mission to provide efficient end-to-end IV safety solutions across a broad journey of care.”

Advertisement

More From Market Realist